---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274022889.md"
description: "Glaukos shares are trading higher after the company announced that the FDA approved an NDA labeling supplement allowing for re-administration of iDose TR using a repeat treatment protocol."
datetime: "2026-01-28T17:10:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274022889.md)
  - [en](https://longbridge.com/en/news/274022889.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274022889.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274022889.md) | [繁體中文](https://longbridge.com/zh-HK/news/274022889.md)


# 

Glaukos shares are trading higher after the company announced that the FDA approved an NDA labeling supplement allowing for re-administration of iDose TR using a repeat treatment protocol.

### Related Stocks

- [Glaukos Corporation (GKOS.US)](https://longbridge.com/en/quote/GKOS.US.md)

## Related News & Research

- [AI Adoption Raises Operational, Regulatory, and Reputational Risks for Glaukos Corp.](https://longbridge.com/en/news/276708178.md)
- [Glaukos (NYSE:GKOS) Director Sells $1,915,650.00 in Stock](https://longbridge.com/en/news/273781430.md)
- [Glaukos’ 2025 Loss, Impairment and ESOP Shelf Might Change The Case For Investing In GKOS](https://longbridge.com/en/news/277607369.md)
- [Glaukos (GKOS) Valuation Check As iDose Sales Momentum Meets Impairment Charge And Upbeat 2026 Outlook](https://longbridge.com/en/news/277346802.md)
- [Glaukos CEO Thomas William Burns Reports Disposal of Common Shares](https://longbridge.com/en/news/273145771.md)